explore -WSS

explore

author：knowledge 2025-10-01 09:00:10 - browse：9263

Nick Leschly - Bluebird Bio — Longtime Bluebird Bio CEO Nick Leschly Wendy Maeda/The Boston Globe

Some two years after splitting biotech company Bluebird Bio into two entities in a bid to “sharpen their focus” and improve operations, the spinout focused on oncology treatments announced major cost cuts and is parting ways with its chief executive.

The spinout, 2Seventy Bio, announced Tuesday that it is cutting approximately 40% of its workforce, or about 176 employees. It also plans to allocate less money to a couple of drug candidates, including one that is currently on hold with the Food and Drug Administration. The cuts extend the company’s cash runway into 2026.

The company was formed in 2021 when the team behind Bluebird Bio decided to split its drug pipeline down the middle. The company was wrestling with its gene therapy portfolio, including getting approval for a gene therapy for the blood disorder beta thalassemia in the U.S. Separately, it had a basket of cancer drug candidates and a partnership with pharma company Bristol Myers Squibb that needed attention. So, Bluebird split its operations in two, with longtime CEO Nick Leschly taking the helm at the new firm.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medical records are filled with copy
Next article： Prior authorization reform is both possible and imperative

knowledge

hotspot

WSS

There's an unseen cost to disruptive road

The Readout: Lisata, Eisai x Biogen, and the Met Gala (!)

Medicare bonuses could stop drug shortages under Senate plan

Update the Apgar Score to remove skin color

Analysis of pharma R&D ranks Novo Nordisk, J&J above their peers

Wearables generate powerful data but its not useful to doctors, yet

focus

explore

Wikipedia

Trump demands the U.S. pay no more for drugs than other countries … again

FDA sets aggressive timeline for overhauling inspection procedures

Activists slam private health insurers over coverage restrictions

Readers respond to H5N1 and livestock movements, and more

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

FDA endorses new sterilization method for medical devices

In Memoriam: Notable people who died in 2023

Addiction experts warn against a second 'war on drugs'

Drug repurposing or repositioning? The language matters

Printout prescription drug information shouldn’t go digital

focus

Readers respond to H5N1 and livestock movements, and more

Microsoft launches AI tool for clinical documentation through Epic

Addiction experts warn against a second 'war on drugs'

Dog Aging Project founders on what lies ahead after losing funding

Readout LOUD podcast: Live from STAT Breakthrough Summit West

Head of FDA's diagnostics center, who led through Covid, retires

leisure time

knowledge

hotspot

focus